Literature DB >> 21348952

Tissue inhibitor of metalloproteinase-2 gene delivery ameliorates postinfarction cardiac remodeling.

Ravi Ramani1, Kathleen Nilles, Gregory Gibson, Benjamin Burkhead, Michael Mathier, Dennis McNamara, Charles F McTiernan.   

Abstract

HYPOTHESIS: Adenoviral-mediated (AdV-T2) overexpression of TIMP-2 would blunt ventricular remodeling and improve survival in a murine model of chronic ischemic injury.
METHODS: Male mice (n = 124) aged 10-14 weeks underwent either (1) left coronary artery ligation to induce myocardial infarction (MI group, n = 36), (2) myocardial injection of 6 × 10¹⁰ viral particles of AdV-T2 immediately post-MI (MI + T2 group, n = 30), (3) myocardial injection of 6 × 10¹⁰ viral particles of a control adenovirus (MI + Ct, n = 38), or 4) received no intervention (controls, n = 20). On post-MI day 7, surviving mice (n = 79) underwent echocardiographic, immunohistochemical, and biochemical analysis.
RESULTS: In infarcted animals, the MI + T2 group demonstrated improved survival (p < 0.02), better preservation of developed pressure and ventricular diameter (p < 0.04), and the lowest expression and activity of MMP-2 and MMP-9 (p < 0.04) compared with MI and MI + Ct groups. All infarcted hearts displayed significantly increased inflammatory cell infiltration (p < 0.04 vs. control, MI, or MI + T2), with infiltration highest in the MI + Ct group and lowest in the MI + T2 group (p < 0.04).
CONCLUSIONS: Adenoviral mediated myocardial delivery of the TIMP-2 gene improves post-MI survival and limits adverse remodeling in a murine model of MI.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21348952      PMCID: PMC3079205          DOI: 10.1111/j.1752-8062.2010.00252.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  38 in total

1.  TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).

Authors:  M Kashiwagi; M Tortorella; H Nagase; K Brew
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

Review 2.  Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.

Authors:  Davy Vanhoutte; Mark Schellings; Yigal Pinto; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2005-12-19       Impact factor: 10.787

3.  Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.

Authors:  Michael P Hudson; Paul W Armstrong; Witold Ruzyllo; Jose Brum; Lisa Cusmano; Piotr Krzeski; Robert Lyon; Miguel Quinones; Pierre Theroux; Diana Sydlowski; Henry E Kim; Mario J Garcia; Wael A Jaber; W Douglas Weaver
Journal:  J Am Coll Cardiol       Date:  2006-06-21       Impact factor: 24.094

4.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis.

Authors:  A H Baker; A B Zaltsman; S J George; A C Newby
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

5.  Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.

Authors:  J T Peterson; H Li; L Dillon; J W Bryant
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

6.  Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice.

Authors:  L E Rohde; A Ducharme; L H Arroyo; M Aikawa; G H Sukhova; A Lopez-Anaya; K F McClure; P G Mitchell; P Libby; R T Lee
Journal:  Circulation       Date:  1999-06-15       Impact factor: 29.690

7.  Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model.

Authors:  Satsuki Mori; Gregory Gibson; Charles F McTiernan
Journal:  J Card Fail       Date:  2006-05       Impact factor: 5.712

8.  Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling.

Authors:  Ravi Ramani; Michael Mathier; Ping Wang; Gregory Gibson; Sandra Tögel; Jennifer Dawson; Anthony Bauer; Sean Alber; Simon C Watkins; Charles F McTiernan; Arthur M Feldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-09       Impact factor: 4.733

9.  TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

Authors:  Dong-Wan Seo; Hongmei Li; Liliana Guedez; Paul T Wingfield; Tere Diaz; Rita Salloum; Bei-yang Wei; William G Stetler-Stevenson
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

10.  TIMP-3 deficiency accelerates cardiac remodeling after myocardial infarction.

Authors:  Hai Tian; Massimo Cimini; Paul W M Fedak; Svetlana Altamentova; Shafie Fazel; Ming-Li Huang; Richard D Weisel; Ren-Ke Li
Journal:  J Mol Cell Cardiol       Date:  2007-09-14       Impact factor: 5.000

View more
  7 in total

Review 1.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

2.  The compendium of matrix metalloproteinase expression in the left ventricle of mice following myocardial infarction.

Authors:  Amanda R Kaminski; Edwin T Moore; Michael J Daseke; Fritz M Valerio; Elizabeth R Flynn; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-21       Impact factor: 4.733

Review 3.  Physiological Implications of Myocardial Scar Structure.

Authors:  William J Richardson; Samantha A Clarke; T Alexander Quinn; Jeffrey W Holmes
Journal:  Compr Physiol       Date:  2015-09-20       Impact factor: 9.090

4.  TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.

Authors:  S Givvimani; S Kundu; N Narayanan; F Armaghan; N Qipshidze; S Pushpakumar; T P Vacek; S C Tyagi
Journal:  Arch Physiol Biochem       Date:  2013-02-11       Impact factor: 4.076

5.  MIQuant--semi-automation of infarct size assessment in models of cardiac ischemic injury.

Authors:  Diana S Nascimento; Mariana Valente; Tiago Esteves; Maria de Fátima de Pina; Joana G Guedes; Ana Freire; Pedro Quelhas; Perpétua Pinto-do-Ó
Journal:  PLoS One       Date:  2011-09-30       Impact factor: 3.240

Review 6.  Extracellular Vesicles as Therapeutic Agents for Cardiac Fibrosis.

Authors:  Russell G Rogers; Alessandra Ciullo; Eduardo Marbán; Ahmed G Ibrahim
Journal:  Front Physiol       Date:  2020-05-21       Impact factor: 4.566

7.  Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease.

Authors:  Dong Fan; Abhijit Takawale; Jiwon Lee; Zamaneh Kassiri
Journal:  Fibrogenesis Tissue Repair       Date:  2012-09-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.